iNstroke 4F 血栓抽吸导管在原发性远端中血管闭塞(DMVO)所致急性缺血性卒中患者中的安全性与有效性评估 (4-NiVO)
前瞻性、单臂、多中心研究,旨在评估iNstroke 4F血栓抽吸导管在原发性远端中等血管闭塞(DMVO)所致急性缺血性卒中患者中的疗效和安全性。
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
研究概览
详细说明
This study is an exploratory, interventional, open label, single-arm, multi-centre prospective clinical investigation.
In this post-market clinical investigation, the aim is to further evaluate the efficacy and safety of the iNstroke 4F aspiration catheter, with a view to, in future clinical investigations, comparing the product with the standard therapy or with other similar products. In addition, this clinical investigation will generate results that could be used to further assess the safety and effectiveness of mechanical thrombectomy for the treatment of DMVO.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Budapest、匈牙利
- Semmelweis University Center
-
-
-
-
-
Bonn、德国
- Universitätsklinikum Bonn
-
Kiel、德国
- Universitätsklinikum Schleswig-Holstein
-
Marburg、德国
- Klinikum Marburg
-
Nuremberg、德国
- Klinikum Nürnberg
-
Recklinghausen、德国
- Knappschaftskrankenhaus Recklinghausen
-
-
-
-
-
Barcelona、西班牙
- Hospital Universitario Vall d'Hebron
-
Madrid、西班牙
- Hospital Universitario 12 de Octubre
-
Madrid、西班牙
- Hospital Universitario La Paz
-
Madrid、西班牙
- Hospital Universitario de Getafe
-
Murcia、西班牙
- Hospital Clínico Universitario Virgen de Arrixaca
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subjects aged ≥ 18 years.
- Subjects with symptom onset up to 24 hours.
- Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
- Baseline NIHSS score ≥5 assessed before the procedure.
- Pre-stroke mRS score ≤ 2.
- Subjects with an ASPECTS score ≥ 6.
- Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
Exclusion Criteria:
- Subjects aged < 18.
- Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO.
- Baseline NIHSS score <5 assessed before the procedure.
- Pre-stroke mRS score >2.
- Subjects with an ASPECTS score <6.
- Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
- Severe allergy to contrast media.
- Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
- Medical history of thrombocytopenia (Platelets <100,000).
- Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
- Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy.
- Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months.
- Subjects participating in a clinical trial at the moment of the inclusion.
- Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Thromboaspiration using iNstroke 4F aspiration catheter
No comparator will be used in this clinical investigation as it is an exploratory study of a CE-marked medical device to be used within the scope of its intended purpose. |
Patients to undergo thromboaspiration with iNstroke 4F |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recanalization Endpoint
大体时间:Intra-procedure
|
Recanalization rate with a modified thrombolysis in cerebral infarction scale (mTICI) score ≥2b in ≤3 revascularization passes using iNstroke 4F aspiration catheter, alone or in conjunction with a SR. |
Intra-procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recanalization Endpoint
大体时间:Intra-procedure
|
Proportion of subjects treated with iNstroke 4F alone with complete recanalization in primary DMVO defined as an mTICI ≥2b, after iNstroke 4F aspiration catheter alone (ADAPT) was used as a first-line therapy |
Intra-procedure
|
|
Recanalization Endpoint
大体时间:Intra-procedure
|
Proportion of subjects treated with iNstroke 4F in conjunction with a stent retriever having complete recanalization in primary DMVO defined as achieving an mTICI ≥2b, after iNstroke 4F aspiration catheter, in conjunction with a stent retriever (SR), was used as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
大体时间:Intra-procedure
|
Proportion of subjects with mTICI≥2b, mTICI≥2c and mTICI 3 after first pass with iNstroke 4F aspiration catheter used both alone and in conjunction with a SR. |
Intra-procedure
|
|
Recanalization Endpoint
大体时间:Intra-procedure
|
Time from groin puncture to achievement of complete recanalization (mTICI ≥2b), or if not achieved, until the final angiogram time, in patients treated with iNstroke 4F aspiration catheter, alone or in conjunction with a SR, as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
大体时间:Intra-procedure
|
Proportion of subjects in which direct contact with thrombus is achieved with iNstroke 4F aspiration catheter. |
Intra-procedure
|
|
Clinical Endpoint
大体时间:90 day
|
Proportion of subjects achieving a modified Rankin scale (mRS) score of 0-2 at the 90-day (±14 days) post-procedure follow-up visit. |
90 day
|
|
Safety Endpoint
大体时间:24 (-8/+12) hours
|
Occurrence of SICH (according to SITS-MOST (13) and ECASS criteria (14)) within 24 (-8/+12) hours post-procedure, assessed by magnetic resonance imaging (MRI)/computed tomography (CT). Intracerebral Haemorrhage (ICH) is defined as the presence of extravascular blood in the brain or within the skull (local or remote parenchymal hematoma type 2, subarachnoid haemorrhage, and/or intraventricular haemorrhage) detected on the post-procedure imaging scan. ICH is considered symptomatic (SICH) if it is associated with a clinical deterioration, determined by a worsening/increase on the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points, or if it causes death and is identified as the predominant cause of neurological deterioration. |
24 (-8/+12) hours
|
|
Safety Endpoint
大体时间:Intra-procedure
|
Occurrence of embolization in a previously non-involved (or new) territory as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
大体时间:Intra-procedure
|
Occurrence of embolization in distal medium territory to the proximal occlusion as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
大体时间:During hospital admission
|
Inhospital mortality rate related to the procedure during hospital admission. |
During hospital admission
|
|
Safety Endpoint
大体时间:90 days (±14 days) after the procedure.
|
Occurrence of devices and procedure related adverse events within 90 days (±14 days) after the procedure. |
90 days (±14 days) after the procedure.
|
|
Safety Endpoint
大体时间:Intra-procedure
|
Occurrence of procedure-related complications: arterial perforation, arterial dissection and severe vasospasm in the target vessel. |
Intra-procedure
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Exploratory Recanalization Endpoint
大体时间:Intra-procedure
|
Proportion of subjects in which a switch of technique (from ADAPT to combined or from combined to ADAPT) with iNstroke 4F aspiration catheter was used to successfully perform the thrombectomy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
大体时间:Intra-procedure
|
Proportion of subjects in which an aspiration catheter device with a 4F caliber different from iNstroke 4F aspiration catheter was used as a rescue therapy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
大体时间:Intra-procedure
|
Proportion of cases in which iNstroke 4F aspiration catheter (alone or in conjunction with a SR) successfully reached the site of occlusion. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
大体时间:Intra-procedure
|
Number of passes with iNstroke 4F aspiration catheter until recanalization. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
大体时间:Intra-procedure
|
Visibility of the catheter during the thrombectomy rated from 0 to 5 (being 0 the worst and 5 the best score). |
Intra-procedure
|
|
Exploratory Clinical Endpoint
大体时间:24 (-8/+12) hours post-procedure.
|
Proportion of subjects with rapid neurological improvement, defined as a decrease of more than 4 points on the NIHSS scale, during the first 24 (-8/+12) hours post-procedure. |
24 (-8/+12) hours post-procedure.
|
|
Exploratory Clinical Endpoint
大体时间:First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
Proportion of subjects with a reduction of ≥8 points on the NIHSS scale during the first 24 (-8/+12) hours post-procedure, or with a NIHSS score of 0-1 at 3 days (±24 hours) or at the time of discharge, whichever occurs first. |
First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
|
Exploratory Clinical Endpoint
大体时间:24 (-8/+12) hours.
|
Median of NIHSS score at 24 (-8/+12) hours. |
24 (-8/+12) hours.
|
|
Exploratory Clinical Endpoint
大体时间:3 days (±24 hours) post procedure
|
Median of NIHSS score at 3 days (±24 hours) or at the time of patient discharge, whichever occurs first. |
3 days (±24 hours) post procedure
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.